DE69609353D1 - In der therapie verwendbare chinolin- und chinazolinverbindungen - Google Patents

In der therapie verwendbare chinolin- und chinazolinverbindungen

Info

Publication number
DE69609353D1
DE69609353D1 DE69609353T DE69609353T DE69609353D1 DE 69609353 D1 DE69609353 D1 DE 69609353D1 DE 69609353 T DE69609353 T DE 69609353T DE 69609353 T DE69609353 T DE 69609353T DE 69609353 D1 DE69609353 D1 DE 69609353D1
Authority
DE
Germany
Prior art keywords
chinazoline
chinoline
therapy
compounds used
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69609353T
Other languages
English (en)
Other versions
DE69609353T2 (de
Inventor
John Collis
Nathan Fox
Julie Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Ltd
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Pfizer Research and Development Co NV SA filed Critical Pfizer Ltd
Publication of DE69609353D1 publication Critical patent/DE69609353D1/de
Application granted granted Critical
Publication of DE69609353T2 publication Critical patent/DE69609353T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69609353T 1995-12-23 1996-12-05 In der therapie verwendbare chinolin- und chinazolinverbindungen Expired - Fee Related DE69609353T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526546.8A GB9526546D0 (en) 1995-12-23 1995-12-23 Compounds useful in therapy
PCT/EP1996/005609 WO1997023462A1 (en) 1995-12-23 1996-12-05 Quinoline and quinazoline compounds useful in therapy

Publications (2)

Publication Number Publication Date
DE69609353D1 true DE69609353D1 (de) 2000-08-17
DE69609353T2 DE69609353T2 (de) 2000-12-07

Family

ID=10786091

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69609353T Expired - Fee Related DE69609353T2 (de) 1995-12-23 1996-12-05 In der therapie verwendbare chinolin- und chinazolinverbindungen

Country Status (34)

Country Link
US (3) US6103738A (de)
EP (1) EP0877734B1 (de)
JP (1) JP3070958B2 (de)
KR (1) KR19990076693A (de)
AP (1) AP715A (de)
AR (1) AR005166A1 (de)
AT (1) ATE194598T1 (de)
AU (1) AU708979B2 (de)
BG (1) BG102559A (de)
BR (1) BR9612263A (de)
CA (1) CA2236814C (de)
CO (1) CO4480106A1 (de)
CZ (1) CZ197698A3 (de)
DE (1) DE69609353T2 (de)
DK (1) DK0877734T3 (de)
ES (1) ES2151192T3 (de)
GB (1) GB9526546D0 (de)
GR (1) GR3034225T3 (de)
HN (1) HN1996000082A (de)
HR (1) HRP960616A2 (de)
HU (1) HUP9903560A3 (de)
IS (1) IS4731A (de)
MA (1) MA26414A1 (de)
NO (1) NO982913L (de)
NZ (1) NZ325248A (de)
OA (1) OA10703A (de)
PL (1) PL327610A1 (de)
PT (1) PT877734E (de)
SK (1) SK81698A3 (de)
TN (1) TNSN96161A1 (de)
TR (1) TR199801195T2 (de)
WO (1) WO1997023462A1 (de)
YU (1) YU68896A (de)
ZA (1) ZA9610784B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
KR100602929B1 (ko) 2000-08-31 2006-07-20 에프. 호프만-라 로슈 아게 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체
EP1363899B1 (de) * 2001-01-02 2005-05-11 F.Hoffmann-La Roche Ag Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP2277867B1 (de) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Verbindungen, pharmazeutische Zusammensetzungen die diese enthalten und ihre Verwendung zur Behandlung von Krebs
EP1556381B1 (de) 2002-09-26 2008-02-20 Pfizer Limited Pyrazolamide zur behandlung von hiv-infektionen
TW200503713A (en) 2003-04-23 2005-02-01 Glaxo Group Ltd Novel compounds
WO2005030131A2 (en) * 2003-09-23 2005-04-07 Replidyne, Inc Bis-quinazoline compounds for the treatment of bacterial infections
ES2371383T3 (es) 2003-09-26 2011-12-30 Exelixis, Inc. N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
RS53895B1 (en) 2004-06-24 2015-08-31 Vertex Pharmaceuticals Incorporated ATP-BINDING CASSETTE TRANSPORT MODULATORS
PL3219705T3 (pl) 2005-12-28 2020-08-10 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu
US8986713B2 (en) * 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
AU2008224941C1 (en) 2007-03-14 2013-06-27 Exelixis Patent Company Llc Inhibitors of the hedgehog pathway
EP2346848B1 (de) 2008-11-14 2013-02-27 F. Hoffmann-La Roche AG Chinazolinderivate als antagonisten des nk3-rezeptors
TW202241853A (zh) 2009-01-16 2022-11-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
SI2821400T1 (en) 2009-03-20 2018-02-28 Vertex Pharmaceuticals Incorporated A process for the manufacture of a transmembrane conductivity regulator in cystic fibrosis
EP2421857B1 (de) * 2009-03-23 2013-08-28 Cipla Limited Verfahren zur herstellung von doxazosin und salzen daraus
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP3575288B1 (de) * 2009-09-03 2021-10-27 Bristol-Myers Squibb Company Chinazoline als kaliumionenkanalhemmer
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
EP3375462B1 (de) 2011-03-11 2023-06-07 W. L. Gore & Associates, Inc. Verbesserungen an immobilisierten biologischen einheiten
US20140309184A1 (en) * 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
EP2819670A1 (de) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmazeutische zusammensetzung und verabreichung davon
EP3124482B1 (de) 2014-03-24 2019-09-11 Guangdong Zhongsheng Pharmaceutical Co., Ltd Chinolinderivate als smo-hemmer
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
AU2017290593A1 (en) 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79603B (de) * 1982-07-24 1984-10-31 Pfizer
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy

Also Published As

Publication number Publication date
NZ325248A (en) 1999-09-29
ATE194598T1 (de) 2000-07-15
JPH11501668A (ja) 1999-02-09
HUP9903560A3 (en) 2000-07-28
BG102559A (en) 1999-03-31
HN1996000082A (es) 1997-06-30
WO1997023462A1 (en) 1997-07-03
KR19990076693A (ko) 1999-10-15
AR005166A1 (es) 1999-04-14
HRP960616A2 (en) 1998-06-30
CO4480106A1 (es) 1997-07-09
GB9526546D0 (en) 1996-02-28
US20020049322A1 (en) 2002-04-25
AP715A (en) 1998-12-30
PT877734E (pt) 2000-12-29
SK81698A3 (en) 2000-04-10
JP3070958B2 (ja) 2000-07-31
ZA9610784B (en) 1998-06-22
DK0877734T3 (da) 2000-11-20
CA2236814A1 (en) 1997-07-03
YU68896A (sh) 1999-07-28
CA2236814C (en) 2001-09-18
DE69609353T2 (de) 2000-12-07
US6642242B2 (en) 2003-11-04
TR199801195T2 (xx) 1998-10-21
HUP9903560A2 (hu) 2000-05-28
EP0877734A1 (de) 1998-11-18
GR3034225T3 (en) 2000-12-29
US6103738A (en) 2000-08-15
EP0877734B1 (de) 2000-07-12
NO982913D0 (no) 1998-06-22
OA10703A (en) 2002-11-28
US6750214B2 (en) 2004-06-15
NO982913L (no) 1998-07-30
IS4731A (is) 1998-04-29
CZ197698A3 (cs) 1999-03-17
AU708979B2 (en) 1999-08-19
AP9600900A0 (en) 1997-01-31
US20030220332A1 (en) 2003-11-27
ES2151192T3 (es) 2000-12-16
TNSN96161A1 (fr) 2005-03-15
AU1371997A (en) 1997-07-17
PL327610A1 (en) 1998-12-21
BR9612263A (pt) 1999-07-13
MA26414A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
DE69609353D1 (de) In der therapie verwendbare chinolin- und chinazolinverbindungen
KR960700239A (ko) 크로만 유도체 및 그의 제약학적 용도(chroman derivative and medicinal use thereof)
BR1100824A (pt) Composto e composição farmacêutica
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
TR199501305A2 (tr) Heterosiklik bilesikler ve bunlarin hazirlanmasi ve kullanimi
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
GB9515775D0 (en) Piperidine derivatives and their use as therapeutic agents
NO972125D0 (no) Hemmoroideblandinger og fremgangsmåte for anvendelse
FI970762A (fi) Terapiassa käyttökelpoiset spiroatsabisykliset yhdisteet
KR970706257A (ko) 치환된 피리딘의 구충제 및 살진균제로서의 용도(use of substituted pyridines as pest-control agents and fungicides)
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
NO992806D0 (no) Terapeutiske midler
ID18679A (id) Penggunaan terapi lanjutan
FI952656A0 (fi) Foerfarande och anordning vid pulsmaetning av en person
FI972245A0 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
FI965204A0 (fi) Bromelaiinin lääkekäyttö
BR9509688A (pt) Composto e composição farmacêutica
KR970702861A (ko) 포르포시아닌 및 cnc-확장된 포르피린(porphocyanine and cnc-expanded porphyrins)
DE69620243D1 (de) Haupt- und nebenstromfilter
FI1031U1 (fi) En troakar
GB9621419D0 (en) 3-3-disubstituted piperidine derivatives and their use as therapeutic agents
ITMI921571A1 (it) Azaciclo e azabiciclo alchiliden idrossilamine
BR9606066A (pt) Composto e formulação farmacêutica
DE59308210D1 (de) Personendurchgang

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee